Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats
Artículo de investigación publicado en The Veterinary Journal
1 de mayo de 2017
The development of new vaccines against animal tuberculosis (TB) is a priority for improving the control and eradication of this disease, particularly in those species not subjected to compulsory eradication programmes. In this study, the protection conferred by the Mycobacterium tuberculosis SO2 experimental vaccine was evaluated using a natural infection model in goats. Twenty-six goats were distributed in three groups: (1) 10 goats served as a control group; (2) six goats were subcutaneously vaccinated with BCG; and (3) 10 goats were subcutaneously vaccinated with SO2. Four months after vaccination, all groups were merged with goats infected with Mycobacterium bovis or Mycobacterium caprae, and tested over a 40 week period using a tuberculin intradermal test and an interferon-γ assay for mycobacterial reactivity. The severity of lesions was determined at post-mortem examination and the bacterial load in tissues were evaluated by culture. The two vaccinated groups had significantly lower lesion and bacterial culture scores than the control group (P < 0.05); at the end of the study, the SO2 vaccinated goats had the lowest lesion and culture scores. These results suggest that the SO2 vaccine provides some protection against TB infection acquired from natural exposure
Bezos J., Casal C., Alvarez J., Roy A., Romero B., Rodriguez-Bertos A., Barcena C., Diez-Guerrier A., Juste R., Gortazar C., Puentes E., Aguilo N., Martin C., de Juan L. y Dominguez L..
 | MAEVA SERVET, S.L.. |
 | Servicio de Micobacterias (MYC). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM). |
 | Department of Veterinary Population Medicine. College of Veterinary Medicine. University of Minnesota (UMM). |
 | Servicio Regional de Investigación y Desarrollo Agroalimentario (SERIDA). Gobierno del Principado de Asturias. |
 | Sanidad y Biotecnología (SaBio). Instituto de Investigación en Recursos Cinegéticos (IREC). Consejo Superior de Investigaciones Científicas (CSIC). Universidad de Castilla La Mancha (UCLM). Gobierno de Castilla-La Mancha (JCCM). |
 | BIOFABRI, S.L.. |
 | Departamento de Microbiología, Medicina Preventiva y Salud Pública. Facultad de Medicina. Universidad de Zaragoza (UNIZAR). |
 | Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Instituto de Salud Carlos III (ISCIII). |
| Servicio de Ensayos Clínicos (SEC). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM). |
